Annual report for Tatva Chintan Pharma Chem Ltd. for FY-2022
25-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter and year ended 31 March 2022, is scheduled on Monday, 25 April 2022 at 05:00 pm IST. The Call is hosted by Investec India and an invite in this regard is attached for your information and records. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.22-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayTatva Chintan Pharma Chem Ltd 2CINL24232GJ1996PLC029894 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 27.47 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ISHWAR NAYI Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: ASHOK BOTHRA Designation: Chief Financial Officer EmailId: [email protected] Date: 20/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.20-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Board to consider Final Dividend
Tatva Chintan Pharma Chem Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on April 25, 2022, inter alia, to:1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022;2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company''s equity shares from April 01, 2022 till the expiry of 48 hours from the date the said financial results are made public.16-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, 25.04.2022
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2022 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2022; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 April 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.15-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Shareholding for the Period Ended March 31, 2022
Tatva Chintan Pharma Chem Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2022. For more details, kindly Click here09-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Submission Of Certificate Under Regulation 40(9) & (10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On 31 March 2022
Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Certificate obtained from M/s. TNT & Associates, Practicing Company Secretaries for the year ended on 31 March 2022. Kindly take the above information on your record.09-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Compliance Certificate For The Period Ended 31 March 2022
Compliance certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2022.07-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201507-04-2022
Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0880 Name of the Signatory :- ISHWAR NAYIDesignation :- Company Secretary and Compliance Officer07-04-2022